Company profile: Cargo Therapeutics
1.1 - Company Overview
Company description
- Provider of CAR T-cell therapies and platforms to overcome cancer treatment resistance and address access barriers. Products include CRG-022 (Firi-cel), a CD22-targeted CAR T for large B-cell lymphoma refractory or relapsed after CD19 CAR T; CRG-023, a tri-specific CAR T targeting CD19/CD20/CD22 with CD2 co-stimulation; a CD2 platform for activation in CD58-lacking tumors; and the STASH platform for multi-gene CAR T engineering.
Products and services
- CRG-023: Custom-engineered CAR T-cell system with CD2 co-stimulation, tri-specifically targeting CD19, CD20, and CD22 to treat various B-cell malignancies
- CRG-022 (Firi-cel): Precision-engineered CAR T-cell product targeting CD22 for large B-cell lymphoma refractory or relapsed after prior CD19 CAR T-cell therapy
- CD2 Platform: Modular technology integrating a CD2 costimulatory domain to enhance CAR T-cell activation against tumors lacking CD58 expression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cargo Therapeutics
Mevion Medical Systems
HQ: United States
Website
- Description: Provider of innovative, safe, and effective radiation therapy solutions for the treatment of cancer, pioneering modern proton therapy systems and transforming advances in medical technology and science into practical clinical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mevion Medical Systems company profile →
IDRx
HQ: United States
Website
- Description: Provider of oncology-based precision therapies for gastrointestinal stromal tumors (GIST). The clinical-stage biopharma designs precision combination medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response. Pipeline includes IDRX-42, a Phase 1 small-molecule tyrosine kinase inhibitor targeting genetic drivers and resistance mutations in GIST, and IDRX-73 targeting a key drug resistance mutation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IDRx company profile →
Aegera Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage targeted therapeutics addressing major unmet medical needs, with three programs in clinical development—two in oncology and one in neuropathic pain—and ongoing identification of novel development candidates based on core technologies. Part of Pharmascience Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegera Therapeutics company profile →
Transgene
HQ: France
Website
- Description: Provider of integrated immunotherapies to treat cancers and chronic infectious diseases, covering research, clinical batch manufacturing, and clinical trials. Portfolio includes TG4050 personalized neoantigen cancer vaccine using genetic engineering and AI; TG4001 therapeutic HPV-16 cancer vaccine; BT-001 (anti-CTLA4, GM-CSF) and TG6050 (IL-12, anti-CTLA4) oncolytic viruses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgene company profile →
IONIQ Sciences
HQ: United States
Website
- Description: Provider of solutions for early detection of multiple cancers to improve survivability and reduce healthcare costs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IONIQ Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cargo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cargo Therapeutics
2.2 - Growth funds investing in similar companies to Cargo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cargo Therapeutics
4.2 - Public trading comparable groups for Cargo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →